Literature DB >> 8043899

Impairment of T-cell growth-promoting lymphokines in human insulin-dependent diabetes mellitus.

G Valerio1, N Gasparini, R Badolato, S Di Maio, A Tenore.   

Abstract

T-cell growth factor (TCGF) activity was studied in phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) from 10 type-1 diabetic patients who had been diagnosed within the previous 12 months (group A), from 9 diabetic patients in whom the duration of disease was more than 1 year (group B) and from 12 healthy controls (group C). The effects of indomethacin on PHA-induced TCGF activity and the effects of adherent cells (macrophages) from group A and group C on TCGF production of normal group-matched non-adherent cells (lymphocytes) were also studied. TCGF activity was assayed on TCGF-dependent blast cells and calculated as a stimulation index (SI). TCGF activity in group A (SI 0.86 +/- 0.8) was significantly different from that in group B (SI 1.75 +/- 1.02; P = 0.037) and in group C (SI 1.91 +/- 1.29; P = 0.023). Following the addition of indomethacin, TCGF SI was 1.35 +/- 0.74 in group A, 1.85 +/- 0.73 in group B and 2.06 +/- 1.19 in group C. The responses to indomethacin were found to correlate with the basal TCGF activity in all subjects (r = -0.48; P = 0.006) independently of the disease process studied or its duration. No correlation was found between TCGF activity and parameters of metabolic control (HBA1c and fructosamine). Interestingly, a significant inverse correlation was found between TCGF activity and the required dose of insulin only in group A (r = -0.66; P < 0.05). Adherent cells from diabetic patients were found not to inhibit TCGF production.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043899     DOI: 10.1007/bf00580762

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  21 in total

1.  IL-4 and IL-2 promote human T-cell proliferation through symmetrical but independent pathways.

Authors:  R Or; H Renz; N Terada; E W Gelfand
Journal:  Clin Immunol Immunopathol       Date:  1992-09

Review 2.  Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat.

Authors:  L Castaño; G S Eisenbarth
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

Review 3.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

Review 4.  Lymphocyte hormone receptors.

Authors:  M Plaut
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

5.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.

Authors:  T Mandrup-Poulsen; K Bendtzen; C A Dinarello; J Nerup
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

6.  Acquired defect in interleukin-2 production in patients with type I diabetes mellitus.

Authors:  W A Kaye; M N Adri; J S Soeldner; S L Rabinowe; A Kaldany; C R Kahn; B Bistrian; S Srikanta; O P Ganda; G S Eisenbarth
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

7.  In vitro and in vivo activated T cells display increased sensitivity to PGE2.

Authors:  R Sunder-Plassmann; O Majdic; W Knapp; W Holter
Journal:  Cell Immunol       Date:  1991-12       Impact factor: 4.868

8.  Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus.

Authors:  K S Zier; M M Leo; R S Spielman; L Baker
Journal:  Diabetes       Date:  1984-06       Impact factor: 9.461

9.  Evidence for initial involvement of macrophage in development of insulitis in NOD mice.

Authors:  K U Lee; K Amano; J W Yoon
Journal:  Diabetes       Date:  1988-07       Impact factor: 9.461

10.  Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages.

Authors:  G J Prud'homme; A Fuks; E Colle; T A Seemayer; R D Guttmann
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.